What is ketamine therapy? Mormon reality stars tout controversial treatment
Season 2 of the reality show "The Secret Lives of Mormon Wives" depicted one couple — Jen and Zac Affleck — as they went through ketamine therapy, which they claimed saved their marriage.
What is ketamine, and can it really benefit relationships?
An anesthetic used to induce sleep before and after surgery, according to Cleveland Clinic, ketamine is also used illegally as a recreational drug.
Fda Approves Opioid-free Pain Medication With 'No Sign Of Addiction'
The Alcohol and Drug Foundation (ADF) describes ketamine as a "dissociative drug," meaning it causes people to feel "separated or detached" from their bodies or physical surroundings.
In recent years, ketamine has been used as an alternative therapy for treatment-resistant depression (TRD).
Read On The Fox News App
"It can be a party drug, and it can be abused, but I think if you have the right intention and you do it in the proper setting with a doctor, it can be super impactful," Zac Affleck said in an interview with Women's Health.
As far as personal beliefs, "there's nothing in the Mormon guidelines that says you can't do ketamine, but it's in the gray area," Affleck added.
In 2019, the U.S. Food and Drug Administration (FDA) approved a derivative of ketamine in a nasal spray format (Spravato, or S-ketamine) for treatment-resistant depression and suicidal ideation.
Some clinical studies have shown that ketamine therapy can be effective in treating severe depression in veterans.
"Ketamine acts like an antidepressant that can help distract someone from negative thoughts and feelings in a relatively short amount of time," Rolando Larice, M.D., medical director at Sana Lake Recovery in Missouri, told Fox News Digital.
Ketamine Therapy Shown Effective In Treating Severe Depression In Veterans, Study Finds
The drug is believed to create more connections between brain cells, a process thought to ease depression and decrease suicidal thoughts, according to Mayo Clinic.
Dr. Justin Gerstner, psychiatrist and chief medical officer at Ellie Mental Health in Minnesota, previously told Fox News Digital that he uses ketamine therapy in his own practice.
"It's been quite transformative for a lot of our clients," he said.
Gerstner's practice usually administers ketamine to clients via IV injection in two- to three-hour sessions, partnered with psychotherapy before and after treatment.
It is intended to be used in combination with antidepressant pills only under the supervision of a medical professional.
At high doses, the drug can cause adverse health issues that affect cardiovascular, respiratory and neurologic function, which can be fatal, said the American Addiction Centers website.
Elon Musk Reveals Why He Takes Ketamine, Denies Abusing The Drug: 'I Should Keep Taking It'
Some risks include elevated blood pressure, difficulty breathing, amnesia, seizures, addiction, problems with judgment and coordination, and a lower urinary tract irritation called ulcerative cystitis, according to the same source.
Click Here To Sign Up For Our Health Newsletter
"Common causes of overdose death include excess sedation, respiratory failure, low blood pressure, cardiac arrhythmia, coma and seizures," Dr. Marc Siegel, Fox News' senior medical advisor, previously told Fox News Digital.
Larice cautioned that ketamine does carry a risk of addiction or dependency.
While ketamine IV therapy could be an alternative option if other treatments haven't been effective for mental health conditions, experts urge caution.
"People may see celebrities like Jen Affleck make claims that ketamine therapy saved her marriage, but if it's shown as a quick fix to solve all of your problems rather than a step toward healing, that's when it can be dangerous," Larice cautioned.
For more Health articles, visit www.foxnews.com/health
It is important for the IV treatment to be monitored by medical professionals in case dangerous side effects occur, he said.
Fox News Digital's Melissa Rudy contributed reporting.Original article source: What is ketamine therapy? Mormon reality stars tout controversial treatment
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
The latest trading session saw Astrazeneca (AZN) ending at $71.93, denoting a -1.24% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.41% for the day. Meanwhile, the Dow experienced a rise of 0.08%, and the technology-dominated Nasdaq saw an increase of 0.67%. Shares of the pharmaceutical witnessed a gain of 0.54% over the previous month, beating the performance of the Medical sector with its loss of 3.74% and underperforming the S&P 500's gain of 6.13%. Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. On that day, Astrazeneca is projected to report earnings of $1.11 per share, which would represent year-over-year growth of 12.12%. Our most recent consensus estimate is calling for quarterly revenue of $14.03 billion, up 8.42% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $4.49 per share and a revenue of $57.68 billion, demonstrating changes of +9.25% and +6.67%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.35% lower. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold). In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 16.2. This valuation marks a discount compared to its industry's average Forward P/E of 20.51. It is also worth noting that AZN currently has a PEG ratio of 1.34. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. AZN's industry had an average PEG ratio of 1.47 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including: Parkinson's Disease (PD), the world's second most prevalent neurodegenerative disease affecting over 10 million patients globally (Phase I clinical trials in both China and the U.S.); Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class; Phase I clinical trials in China and the U.S.); and Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class; Phase I/II clinical trial in China and Phase I in the U.S.; designated as an Orphan Drug by the U.S. FDA). XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with Parkinson's disease, including"the first case"in China. This clinical study was approved by the National Health Commission (NHC) of China. In the clinical study, clinical-grade iPSC-derived dopaminergic neural progenitor cells were transplanted into the putamen of the striatum in patients with moderate to advanced Parkinson's disease. With follow-up periods exceeding 12 months, no cell therapy-related adverse events have been observed. Multiple patients showed significant improvements in key efficacy indicators, including"on/off"time duration and MDS-UPDRS scores, as well as notable enhancements in non-motor symptoms. XellSmart is committed to developing clinical-grade, off-the-shelf allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, was granted by FDA as Orphan Drug Designation (ODD) for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, China's first national-level registered clinical study of an iPSC-derived cell therapy for Parkinson's disease—also developed by XellSmart—was approved and initiated, including the first case treated in China. In 2024, the world's first national-level registered clinical study of a subtype-specific iPSC-derived neural progenitor cell therapy (XS228 injection) for ALS was approved. Multiple patients, including the world's first ALS case treated with this approach, received therapy with good safety profiles and preliminary data showing slowed disease progression. In 2025, China's first registrational Phase I clinical trial of an off-the-shelf allogeneic iPSC-derived dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson's disease was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital. In 2025, China's first randomized, double-blind, controlled Phase I/II clinical trial of XS411 injection was initiated to treat early-onset Parkinson's disease (EOPD), led by Huashan Hospital of Fudan University, a National Neurological Disease Medical Center. In 2025, the world's first registrational Phase I clinical trial of an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy was launched by The Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI) — a major neurological disorder with no effective treatment. In 2025, the world's first Phase I/II registrational clinical trial of XS228 injection—an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy—was initiated by Peking University Third Hospital, targeting ALS, a devastating rare neurodegenerative disease. XellSmart has established a fully dedicated, internationally competitive "All-In" team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. To develop iPSC-derived cell therapy candidates, XellSmart has established and operates an R&D center, a B+ and A-grade GMP manufacturing facility, and a quality control center spanning over 5,000 square meters. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple clinical trials. XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others. View original content: SOURCE XellSmart Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Exercise may stop colon cancer from returning — and more
For Monday, June 2, WGN's Ben Bradley and Lourdes Daurte have the latest on new medical information, including: More Coverage: WGN's Medical Watch Exercise may help prevent colon cancer from returning, according to results from a late-phase trial published Sunday, June 1 in the New England Journal of Medicine. The study looked at people who followed an exercise program after undergoing surgery and chemotherapy for Stage 3, or high-risk Stage 2 colon cancer. It found exercise could reduce the risk of the cancer returning, a new cancer diagnosis, or death by 28 percent. The study participants who reduced their risk had a coach assist them in exercising over the eight-year study period. The CDC is urging Americans to cancel their upcoming flights if they're not vaccinated against measles. The agency upgraded its health travel warning after discovering the virus is spreading on US airplanes. Measles infections have been detected at the country's biggest airports in recent months during a resurgence of the virus linked to low vaccination rates. It's estimated that around 10 percent of adults may lack immunity, either because they never received a measles vaccine or because their immunity has diminished over time. Moderna has won FDA approval for a new version of the COVID-19 vaccine. It will be made available during the upcoming respiratory virus season to people aged 65 and older, and those aged 12 to 64 with at least one underlying health condition that puts them at severe risk. It's the first big approval by the FDA since it required drug companies to expand their testing. The new vaccine is called MNEXSPIKE. Sign up for our Medical Watch newsletter. This daily update includes important information from WGN's Dina Bair and the Med Watch team, including, the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments, as well as personal features related to people in the medical field. Sign up here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
